Initial public offering of Orphazyme (DK) on Nasdaq Copenhagen — DKK 600 million

Carnegie acted as joint global co-ordinator and joint bookrunner in the initial public offering of Orphazyme on Nasdaq Copenhagen. Orphazyme is a Danish biotech company with a late stage orphan drug pipeline, developing new treatment options for orphan protein misfolding diseases. November 2017.